• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    1/10/23 4:31:08 PM ET
    $AEMD
    $ALZN
    $AVRO
    $AYLA
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEMD alert in real time by email

    Gainers

    • Hepion Pharmaceuticals (NASDAQ:HEPA) stock increased by 72.2% to $0.79 during Tuesday's after-market session. At the close, Hepion Pharmaceuticals's trading volume reached 954.9K shares. This is 348.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $60.3 million.
    • Tivic Health Systems (NASDAQ:TIVC) shares rose 16.89% to $0.64. The company's market cap stands at $6.1 million.
    • Lixte Biotech Hldgs (NASDAQ:LIXT) shares increased by 10.28% to $0.59. The company's market cap stands at $9.8 million.
    • Nutex Health (NASDAQ:NUTX) stock moved upwards by 8.04% to $1.88. The company's market cap stands at $1.2 billion.
    • Alzamend Neuro (NASDAQ:ALZN) shares rose 8.02% to $0.59. The company's market cap stands at $57.3 million.
    • EUDA Health Holdings (NASDAQ:EUDA) stock moved upwards by 6.58% to $1.78. The market value of their outstanding shares is at $39.8 million.

    Losers

    • Ayala Pharmaceuticals (NASDAQ:AYLA) shares decreased by 12.2% to $0.48 during Tuesday's after-market session. The market value of their outstanding shares is at $7.1 million.
    • Revelation Biosciences (NASDAQ:REVBU) stock declined by 10.72% to $0.25.
    • Avrobio (NASDAQ:AVRO) stock fell 7.91% to $0.8. The company's market cap stands at $35.0 million.
    • Frequency Therapeutics (NASDAQ:FREQ) shares declined by 7.48% to $3.59. The market value of their outstanding shares is at $126.5 million.
    • Qualigen Therapeutics (NASDAQ:QLGN) shares decreased by 7.45% to $1.24. Trading volume for this security closed at 2.3 million, accounting for 2669.9% of its average full-day volume over the last 100 days. The company's market cap stands at $5.2 million.
    • Aethlon Medical (NASDAQ:AEMD) stock decreased by 5.81% to $0.43. The company's market cap stands at $9.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $ALZN
    $AVRO
    $AYLA

    CompanyDatePrice TargetRatingAnalyst
    Aethlon Medical Inc.
    $AEMD
    7/7/2025$1.50Neutral
    H.C. Wainwright
    Nutex Health Inc.
    $NUTX
    11/12/2024$45.00 → $50.00Buy
    Maxim Group
    Nutex Health Inc.
    $NUTX
    9/18/2024$45.00Buy
    Maxim Group
    AVROBIO Inc.
    $AVRO
    12/18/2023Buy → Neutral
    Mizuho
    Nutex Health Inc.
    $NUTX
    2/22/2023$3.00Outperform
    Northland Capital
    Frequency Therapeutics Inc.
    $FREQ
    2/15/2023Buy → Neutral
    Chardan Capital Markets
    Frequency Therapeutics Inc.
    $FREQ
    2/13/2023Outperform → Market Perform
    Cowen
    Hepion Pharmaceuticals Inc.
    $HEPA
    2/28/2022$3.50Overweight
    Cantor Fitzgerald
    More analyst ratings

    $AEMD
    $ALZN
    $AVRO
    $AYLA
    SEC Filings

    View All

    SEC Form 10-K filed by Lixte Biotechnology Holdings Inc.

    10-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

    3/31/26 3:12:24 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Tivic Health Systems Inc.

    10-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/30/26 5:34:51 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Health Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/25/26 4:25:57 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AEMD
    $ALZN
    $AVRO
    $AYLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Aethlon Medical with a new price target

    H.C. Wainwright resumed coverage of Aethlon Medical with a rating of Neutral and set a new price target of $1.50

    7/7/25 8:15:50 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Maxim Group reiterated coverage on Nutex Health with a new price target

    Maxim Group reiterated coverage of Nutex Health with a rating of Buy and set a new price target of $50.00 from $45.00 previously

    11/12/24 8:15:57 AM ET
    $NUTX
    Real Estate

    Maxim Group initiated coverage on Nutex Health with a new price target

    Maxim Group initiated coverage of Nutex Health with a rating of Buy and set a new price target of $45.00

    9/18/24 8:12:45 AM ET
    $NUTX
    Real Estate

    $AEMD
    $ALZN
    $AVRO
    $AYLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Valauri Christina Rizopoulos

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    4/2/26 9:49:13 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Shah Chetan

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    4/1/26 7:27:48 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Gikakis Nicolas

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    4/1/26 7:27:34 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    $ALZN
    $AVRO
    $AYLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer-Healthcare Montgomery Pamela W. bought $7,021 worth of shares (79 units at $88.87), increasing direct ownership by 3% to 2,758 units (SEC Form 4)

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/16/26 3:02:43 PM ET
    $NUTX
    Real Estate

    Chief Financial Officer Bates Jon Christian bought $102,532 worth of shares (750 units at $136.71), increasing direct ownership by 15% to 5,638 units (SEC Form 4)

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    11/28/25 2:11:24 PM ET
    $NUTX
    Real Estate

    Chief Financial Officer Bates Jon Christian converted options into 1,611 shares and bought $81,810 worth of shares (1,000 units at $81.81), increasing direct ownership by 115% to 4,888 units (SEC Form 4)

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    4/14/25 4:30:48 PM ET
    $NUTX
    Real Estate

    $AEMD
    $ALZN
    $AVRO
    $AYLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live stream

    MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting TodayWednesday, April 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you a

    4/1/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

    BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has filed its Annual Report on Form 10-K for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The report is available on the Company's website, www.lixte.com, and on the SEC's website, www.sec.gov. "2025 was a transformative and highly productive year for our Company," said Geordan Pursglove, who was named LIXTE's Chairman and Chief Executive Officer in June 2025. "We strengthened LIXTE's foundation by assembling an

    3/31/26 3:45:00 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Presenting on Emerging Growth Conference 91 Day 1 on April 1; Register to live stream

    MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdayApril 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to

    3/31/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    $AEMD
    $ALZN
    $AVRO
    $AYLA
    Leadership Updates

    Live Leadership Updates

    View All

    Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

    Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in

    2/23/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

    BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company's Liora Technologies Europe Ltd. subsidiary ("Liora"). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE's acquisition of Liora's assets in November 2025 from Orbit Capital, Inc. Over his

    2/18/26 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community,

    10/22/25 2:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AEMD
    $ALZN
    $AVRO
    $AYLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hepion Pharmaceuticals Inc.

    SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

    11/14/24 4:07:59 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Nutex Health Inc.

    SC 13G - Nutex Health, Inc. (0001479681) (Subject)

    11/14/24 11:02:17 AM ET
    $NUTX
    Real Estate

    SEC Form SC 13D filed by AVROBIO Inc.

    SC 13D - Tectonic Therapeutic, Inc. (0001681087) (Subject)

    6/26/24 8:00:02 AM ET
    $AVRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEMD
    $ALZN
    $AVRO
    $AYLA
    Financials

    Live finance-specific insights

    View All

    LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

    BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has filed its Annual Report on Form 10-K for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The report is available on the Company's website, www.lixte.com, and on the SEC's website, www.sec.gov. "2025 was a transformative and highly productive year for our Company," said Geordan Pursglove, who was named LIXTE's Chairman and Chief Executive Officer in June 2025. "We strengthened LIXTE's foundation by assembling an

    3/31/26 3:45:00 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM

    FULL YEAR 2025 HIGHLIGHTS:Total revenue of $875.3 million for the year 2025 versus $479.9 million for the year 2024, an increase of 82.4%Net income attributable to Nutex Health of $70.8 million for 2025 versus net income of $52.1 million for 2024, an increase of $18.7 millionDiluted EPS of $10.48 for 2025 versus diluted EPS of $9.69 for 2024EBITDA of $168.6 million for 2025 versus $98.8 million for 2024, an increase of 70.6%Adjusted EBITDA of $259.6 million for 2025 versus $102.8 million for 2024, an increase of 152.6%Net cash from operating activities of $248.1 million for 2025HOUSTON, March 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), today ann

    3/5/26 6:33:00 PM ET
    $NUTX
    Real Estate

    Nutex Health Schedules 2025 Fourth Quarter and Year-End Financial Results and Earnings Conference Call

    HOUSTON, Feb. 25, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, on Thursday, March 5, 2026, after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, March 6, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and

    2/25/26 5:29:00 PM ET
    $NUTX
    Real Estate